IPSS Risk Category Intermediate-1
1 clinical trials · Condition
◉ Watch IPSS Risk Category Intermediate-1
| Record | Firm | Date |
|---|---|---|
| Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome (NCT03094637) | M.D. Anderson Cancer Center | 2017-11-06 |
Track IPSS Risk Category Intermediate-1 automatically
Every clearance here is in the API, with alerts when new ones post.